A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer

By sjmartinez • June 28, 2025

Lloyd MR, Chica-Parrado R, Weipert CM, Knepper TC, Podany EL, Napolitano F, Ye D, Lin CC, Uemoto Y, Liao J, Wegrzyn C, Walko CM, Ryan LY, Keenan JC, Medford AJ, Liu SA, Wulf GM, Clifton KK, Ma CX, Han HS, Zhang N, Ellisen LW, Bardia A, Arteaga CL, Hanker AB, Wander SA. A bedside-to-bench translational analysis of NF1 alterations and CDK4/6 inhibitor resistance in hormone receptor-positive metastatic breast cancer. EBioMedicine. 2025 Jun 26;118:105828. doi: 10.1016/j.ebiom.2025.105828. Epub ahead of print. PMID: 40578027.

Tags: CDK4/6 inhibitor, Hematology/Oncology, HR+ breast cancer, metastatic breast cancer, NF1 mutation, Precision medicine, Publications, Resistance mechanisms

Related Posts

Blinatumomab Nonresponse Correlates with Poor Survival After Brexucabtagene

Srinagesh HK, Gupta VK, Zhang A, Grunwald MR, Connor MP, Kota VK, Boccucci J, Ulrickson ML, Pradeep R, Hill LC, Tsai SB, O'Connor TE, Sandhu[...]

Neoadjuvant Stereotactic Body vs. Conventionally Fractionated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis

Shimizu T, Zheng S, Maeda S, Link J, Deranteriassian A, Premji A, King J, Girgis M, Hines OJ, Wainberg Z, Raldow A, He J, Burns[...]

Author Correction: Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis

Li S, Noor ZS, Zeng W, Stackpole ML, Ni X, Zhou Y, Yuan Z, Wong WH, Agopian VG, Dubinett SM, Alber F, Li W, Garon[...]